GO:0002264 endothelial cell activation involved in immune response: Immune-Vascular Crosstalk, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002264 describes the morphological and behavioral change of an endothelial cell after exposure to an activating factor such as a cellular or soluble ligand, which initiates or perpetuates an immune response.
• Endothelial activation is a central hub in sepsis, where neutrophils and neutrophil extracellular traps drive endothelial dysfunction and vascular leakage.
• Single-cell atlases have identified distinct immunomodulatory and lipid-processing endothelial subsets in healthy and malignant breast tissue, showing that activation states are transcriptionally heterogeneous.
• Interleukin-33 (IL-33) is released as a potent extracellular cytokine that can act on endothelial and immune cells, linking alarmin signaling to endothelial activation.
• In giant cell arteritis, complement-dendritic cell-endothelial crosstalk and STING-JAK1 signaling are emerging as key amplifiers of vascular inflammation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test causality of candidate genes in endothelial activation and immune response.
Description
GO:0002264, endothelial cell activation involved in immune response, is a biological process term that captures the transition of endothelial cells from a resting, barrier-forming state to an activated, immune-interactive state. According to the QuickGO definition, this process is a change in the morphology or behavior of an endothelial cell resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response. In practical terms, this term is used by researchers who study how blood vessels participate in inflammation, host defense, and immune-mediated tissue injury. The importance of this term spans sepsis, autoimmunity, atherosclerosis, and cancer, where endothelial activation determines leukocyte recruitment, vascular permeability, and tissue outcome. For example, in sepsis, neutrophils and neutrophil extracellular traps directly promote endothelial cell dysfunction, a process that fits the definition of GO:0002264 and contributes to organ failure. In giant cell arteritis, advances in pathogenesis have highlighted how dendritic cells, complement, and endothelial cells crosstalk to sustain vascular inflammation. Single-cell transcriptomics has further revealed that endothelial activation is not a single uniform state but a spectrum of immunomodulatory and lipid-processing phenotypes in healthy and malignant tissues. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links, and experimental models relevant to GO:0002264.
endothelial cell activation involved in immune response At A Glance
| GO ID | GO:0002264 |
|---|---|
| GO term | endothelial cell activation involved in immune response |
| Ontology | biological_process |
| Synonym | endothelial cell activation during immune response |
| Definition | A change in the morphology or behavior of an endothelial cell resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response. |
| Major function | Enables endothelial cells to participate in immune responses by altering morphology, surface phenotype, and behavior after exposure to activating factors. |
| Related processes | Leukocyte adhesion and recruitment, vascular permeability, cytokine and chemokine release, complement and dendritic cell crosstalk. |
| Disease relevance | Sepsis, giant cell arteritis, atherosclerosis, cerebrovascular events, and tumor immunity. |
| Research methods | Single-cell RNA profiling, STING-JAK1 pathway analysis, neutrophil extracellular trap assays, and CRISPR-based gene editing. |
What Is GO:0002264?
In our own words, GO:0002264 refers to the process by which an endothelial cell changes its shape, surface molecule expression, or behavior after encountering an activating factor, such as a cytokine, complement component, or a ligand on another cell. This change is not merely a passive response; it is a functional transition that enables the endothelium to participate in immune responses, for example by promoting leukocyte adhesion, altering barrier function, or releasing immune-active mediators. The term is explicitly tied to the initiation or perpetuation of an immune response, distinguishing it from generic endothelial activation that may occur in non-immune contexts. The synonym endothelial cell activation during immune response is used interchangeably in the literature.
Why Is endothelial cell activation involved in immune response Important in Cell Biology?
GO:0002264 is important because endothelial activation is a decisive checkpoint that converts the vasculature from a passive conduit into an active immune organ. When endothelial cells become activated, they can capture circulating leukocytes, modulate vascular permeability, and secrete mediators that amplify or resolve inflammation. This process is directly implicated in the pathogenesis of sepsis, where neutrophil extracellular traps and endothelial dysfunction contribute to multi-organ failure. It is also central to large-vessel vasculitis such as giant cell arteritis, where complement-dendritic cell-endothelial crosstalk sustains vascular inflammation. In cancer, endothelial STING-JAK1 interaction can promote tumor vasculature normalization and antitumor immunity, showing that endothelial activation states can be therapeutically harnessed. Single-cell studies of carotid atherosclerosis and cerebrovascular events have identified endothelial subsets with distinct immune functions, reinforcing the idea that GO:0002264 is not a single state but a heterogeneous program. Therefore, understanding the genes and signals that control this process is essential for developing targeted therapies that modulate vascular immune responses without disrupting normal barrier function.
• Endothelial activation is a hallmark of sepsis-associated vascular dysfunction and organ injury.
• Neutrophil extracellular traps directly promote endothelial cell dysfunction, linking innate immune effectors to GO:0002264.
• Single-cell atlases reveal immunomodulatory endothelial subsets in breast tissue, showing heterogeneity in activation states.
• IL-33 released as an extracellular cytokine can act on endothelial and immune cells, connecting alarmins to endothelial activation.
• Giant cell arteritis pathogenesis involves complement-dendritic cell-endothelial crosstalk, a direct example of immune-mediated endothelial activation.
• Pulmonary capillary responses to sepsis-induced acute lung injury involve endothelial activation programs.
• Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity.
• Carotid atherosclerosis and cerebrovascular events are associated with distinct endothelial cell subsets and functional heterogeneity.
• Targeting endothelial activation genes with CRISPR models can reveal causal drivers of immune-vascular crosstalk.
• GO:0002264 provides a standardized framework for comparing endothelial immune activation across diseases and model systems.
What Happens During endothelial cell activation involved in immune response?
Triggering by soluble and cellular ligands
In simple terms: The endothelium first receives an alarm signal from the immune system or damaged tissue.
Endothelial activation begins when endothelial cells are exposed to activating factors such as cytokines, complement components, or ligands presented by immune cells. In sepsis, neutrophils and neutrophil extracellular traps release factors that directly promote endothelial cell dysfunction, initiating the activation program. Interleukin-33 (IL-33) is released as a potent extracellular cytokine that can act on endothelial cells and immune cells, providing a soluble trigger for activation. Complement-dendritic cell-endothelial crosstalk in vascular inflammation further illustrates how cellular and soluble ligands converge on the endothelium.
Morphological and behavioral changes
In simple terms: The endothelial cell changes its shape and behavior to become sticky and interactive with immune cells.
After exposure to activating factors, endothelial cells undergo changes in morphology and behavior, including altered surface molecule expression, cytoskeletal rearrangement, and increased permeability. In sepsis, these changes contribute to vascular leakage and organ dysfunction. Single-cell RNA profiling of pulmonary capillaries in sepsis-induced acute lung injury has revealed transcriptional programs consistent with such behavioral shifts. The QuickGO definition explicitly includes changes in morphology or behavior as part of GO:0002264.
Immune cell recruitment and adhesion
In simple terms: The activated endothelium grabs passing immune cells and helps them enter the tissue.
A key functional outcome of endothelial activation is the recruitment and adhesion of leukocytes. In giant cell arteritis, dendritic cells and complement components interact with endothelial cells to promote vascular inflammation and immune cell infiltration. Neutrophil-endothelial interactions in sepsis are a classic example of this recruitment process, where activated endothelium facilitates neutrophil adhesion and subsequent tissue damage. This step directly fulfills the definitional requirement of initiating or perpetuating an immune response.
Amplification via intracellular signaling
In simple terms: Signals inside the endothelial cell amplify the activation and keep the immune response going.
Intracellular signaling pathways amplify and sustain endothelial activation. Endothelial STING-JAK1 interaction has been shown to promote tumor vasculature normalization and antitumor immunity, indicating that STING-JAK1 signaling is a functional module within activated endothelium. In carotid atherosclerosis and cerebrovascular events, single-cell transcriptomics has revealed crucial endothelial cell subsets with functional heterogeneity, suggesting that distinct intracellular programs drive different activation states. These signaling events help perpetuate the immune response as described in GO:0002264.
Resolution or chronic perpetuation
In simple terms: The activation can either shut down or become chronic, depending on the context.
Endothelial activation can resolve after the triggering factor is cleared, or it can become chronic and contribute to persistent vascular inflammation. In giant cell arteritis, advances in understanding pathogenesis have highlighted how ongoing complement-dendritic cell-endothelial crosstalk can sustain disease. In cancer, endothelial STING-JAK1 interaction can promote antitumor immunity, suggesting that activation states can be therapeutically directed toward resolution or immune-mediated tumor control. The balance between resolution and chronic perpetuation determines clinical outcome in diseases linked to GO:0002264.
Key Genes Involved in GO:0002264 endothelial cell activation involved in immune response
The following genes and proteins have been implicated in endothelial cell activation involved in immune response based on the verified literature, and they represent candidate targets for CRISPR-based functional studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STING1 | Intracellular signaling adaptor that interacts with JAK1 to promote tumor vasculature normalization and antitumor immunity | CRISPR knockout or point mutation to test STING-JAK1 interaction in endothelial activation |
| JAK1 | Kinase that interacts with STING in endothelial cells to modulate immune-vascular crosstalk | Knock-in of kinase-dead or constitutively active JAK1 to dissect signaling |
| IL33 | Alarmin cytokine released extracellularly that can act on endothelial and immune cells | Overexpression or knockout to study IL-33-driven endothelial activation |
| Complement components (e.g., C3, C5) | Soluble ligands that participate in complement-dendritic cell-endothelial crosstalk | CRISPR knockout in endothelial cells to test complement-dependent activation |
| Dendritic cell ligands | Cellular ligands that interact with endothelial cells during vascular inflammation | Co-culture models with CRISPR-edited endothelial cells |
| Neutrophil-derived factors | Soluble and cellular factors including neutrophil extracellular traps that promote endothelial dysfunction | Neutrophil-endothelial co-culture with gene-edited endothelium |
| Pulmonary capillary endothelial markers | Genes identified by single-cell RNA profiling in sepsis-induced acute lung injury | Single-cell CRISPR screens to identify causal drivers |
| Atherosclerosis-associated endothelial genes | Genes defining endothelial subsets in carotid atherosclerosis and cerebrovascular events | Knockout and overexpression in endothelial cell models |
| Breast immunomodulatory endothelial genes | Genes marking lipid-processing and immunomodulatory endothelial cells in breast tissue | Single-cell transcriptomics and CRISPR validation |
| Adhesion molecules (e.g., selectins, integrins) | Mediate leukocyte adhesion during endothelial activation | CRISPR knockout to block immune cell recruitment |
| Chemokines | Secreted mediators that recruit immune cells to activated endothelium | Overexpression or knockout to test recruitment |
| Barrier junction proteins | Maintain or modulate vascular permeability during activation | Point mutations to alter barrier function |
| STING pathway downstream effectors | Transcription factors and cytokines downstream of STING-JAK1 | Knock-in reporters to monitor pathway activity |
| Complement receptors | Bind complement components during crosstalk | Knockout to test ligand-receptor interactions |
| IL-33 receptor (ST2/IL1RL1) | Mediates IL-33 signaling in endothelial and immune cells | Knockout or point mutation to block IL-33 response |
| Neutrophil extracellular trap components | Directly promote endothelial dysfunction | In vitro assays with CRISPR-edited endothelium |
| Vascular normalization genes | Genes downstream of STING-JAK1 that normalize tumor vasculature | Overexpression and knockout in tumor endothelial models |
| Cerebrovascular event-associated endothelial genes | Genes linked to functional heterogeneity in carotid atherosclerosis | Single-cell CRISPR screening in endothelial cells |
How Is endothelial cell activation involved in immune response Regulated?
Endothelial cell activation involved in immune response is regulated at multiple levels, including soluble ligand availability, receptor expression, and intracellular signaling. IL-33 release as an extracellular cytokine is a regulated event that can trigger endothelial activation. Complement-dendritic cell-endothelial crosstalk provides a regulatory loop where complement components and dendritic cell ligands modulate endothelial behavior. Intracellularly, STING-JAK1 interaction acts as a signaling node that can promote vasculature normalization and antitumor immunity, indicating that this pathway regulates the balance between activation and normalization. Neutrophil extracellular traps and neutrophil-derived factors also regulate endothelial dysfunction in sepsis, creating a feedback loop between innate immune cells and the endothelium. Single-cell studies in atherosclerosis and breast tissue have revealed that endothelial activation states are transcriptionally heterogeneous, suggesting that cell-intrinsic regulatory programs determine the specific activation phenotype.
endothelial cell activation involved in immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STING1 | Tumor vasculature normalization and antitumor immunity | Knockout and knock-in endothelial cell lines; tumor co-culture models |
| JAK1 | Endothelial immune-vascular crosstalk in cancer | Point mutation of kinase domain; STING-JAK1 interaction assays |
| IL33 | Alarmin-driven vascular inflammation | Overexpression and knockout in endothelial cells; cytokine release assays |
| Complement components | Giant cell arteritis and vascular inflammation | CRISPR knockout in endothelial cells; dendritic cell co-culture |
| Neutrophil-derived factors | Sepsis-associated endothelial dysfunction | Neutrophil-endothelial co-culture with gene-edited endothelium |
Sepsis and acute lung injury
In sepsis, neutrophil extracellular traps and neutrophil-derived factors directly promote endothelial cell dysfunction, a process that matches GO:0002264 and contributes to vascular leakage and organ failure. Lung single-cell RNA profiling in sepsis-induced acute lung injury has revealed pulmonary capillary responses that include endothelial activation programs. These findings position endothelial activation as a therapeutic target in sepsis and acute respiratory distress syndrome.
Giant cell arteritis and vascular inflammation
Giant cell arteritis is a large-vessel vasculitis in which complement-dendritic cell-endothelial crosstalk sustains vascular inflammation. Advances in understanding pathogenesis have highlighted the role of endothelial activation in recruiting immune cells and perpetuating arterial damage. The complement-dendritic cell-endothelial axis provides a direct example of GO:0002264 in human disease.
Atherosclerosis and cerebrovascular events
Single-cell transcriptomics of carotid atherosclerosis and cerebrovascular events has identified crucial endothelial cell subsets and functional heterogeneity associated with disease. These subsets likely represent different activation states within GO:0002264, and their identification provides candidate genes for functional studies. Endothelial activation in this context contributes to plaque instability and thromboembolic events.
Cancer and tumor immunity
Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity, demonstrating that endothelial activation can be beneficial in cancer. Single-cell atlas studies in breast cancer have identified lipid-processing and immunomodulatory endothelial cells, suggesting that distinct activation states exist in tumors. Modulating GO:0002264-related pathways may therefore be a strategy to improve immunotherapy responses.
From endothelial cell activation involved in immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is STING1 required for endothelial activation and antitumor immunity? | STING1 knockout endothelial cells in tumor co-culture and vasculature normalization assays |
| Does JAK1 kinase activity mediate STING-dependent endothelial activation? | JAK1 point-mutation knock-in endothelial cells |
| Does IL-33 act directly on endothelial cells to trigger activation? | IL33 overexpression and IL1RL1 knockout endothelial cells |
| Which complement components drive endothelial-dendritic cell crosstalk? | Complement gene knockout endothelial cells in co-culture with dendritic cells |
| Which endothelial genes are causal in sepsis-induced lung injury? | Single-cell CRISPR screening in pulmonary endothelial cells |
| What endothelial subsets drive cerebrovascular events? | Knock-in reporter endothelial cells for subset-specific markers |
How to Study the endothelial cell activation involved in immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-cell RNA sequencing | Transcriptional heterogeneity of endothelial cells | Identifying activation subsets in sepsis, atherosclerosis, and cancer |
| Co-immunoprecipitation | Protein-protein interactions such as STING-JAK1 | Testing endothelial signaling complexes |
| Phospho-immunoblotting | Kinase activation such as JAK1 phosphorylation | Measuring STING-JAK1 pathway activity |
| Neutrophil-endothelial co-culture | Endothelial dysfunction induced by neutrophils and NETs | Modeling sepsis-associated endothelial activation |
| Complement activation assays | Complement deposition and crosstalk with dendritic cells | Studying vascular inflammation in giant cell arteritis |
| Cytokine release assays | Secretion of IL-33 and other mediators | Testing alarmin-driven endothelial activation |
| CRISPR knockout screening | Causal genes required for endothelial activation | Functional genomics of GO:0002264 |
| Knock-in reporter assays | Pathway activity and subset-specific markers | Monitoring activation states in live endothelial cells |
Single-cell RNA profiling
Single-cell RNA profiling has been used to identify endothelial cell subsets and functional heterogeneity in sepsis-induced acute lung injury, carotid atherosclerosis, and breast cancer. This method allows researchers to resolve distinct activation states within GO:0002264 and to nominate candidate genes for functional validation. When combined with CRISPR editing, it can link genotype to transcriptional phenotype at single-cell resolution.
STING-JAK1 pathway analysis
Endothelial STING-JAK1 interaction can be studied using co-immunoprecipitation, proximity ligation, and phospho-JAK1 immunoblotting in endothelial cells. These methods measure the signaling events that promote tumor vasculature normalization and antitumor immunity. CRISPR knockout or point mutation of STING1 or JAK1 can test causality of the interaction.
Neutrophil-endothelial co-culture and NET assays
Neutrophil extracellular traps and neutrophil-derived factors can be studied in co-culture with endothelial cells to measure endothelial dysfunction and activation markers. These assays are relevant to sepsis and can be combined with CRISPR-edited endothelium to identify genes that mediate neutrophil-induced activation.
Complement and dendritic cell crosstalk assays
Complement-dendritic cell-endothelial crosstalk can be modeled using co-culture systems and complement activation assays. These methods help dissect how soluble and cellular ligands trigger GO:0002264 in vascular inflammation. CRISPR knockout of complement components or receptors in endothelial cells can reveal ligand-receptor requirements.
How CRISPR Can Be Used to Study GO:0002264 endothelial cell activation involved in immune response
Knockout
CRISPR knockout of candidate genes such as STING1, JAK1, or complement components in endothelial cells can test whether they are required for endothelial activation involved in immune response. Knockout models are particularly useful for loss-of-function studies in sepsis, vasculitis, and cancer. By comparing knockout and wild-type endothelial cells in co-culture or single-cell assays, researchers can determine causality.
Point Mutation
Point mutation knock-in can be used to dissect specific residues or domains, such as the kinase domain of JAK1 or ligand-binding residues of IL-33 receptor. These models allow precise testing of signaling mechanisms without completely abolishing protein expression. Point mutations are valuable for studying gain-of-function or separation-of-function phenotypes in GO:0002264.
Knock-in
Knock-in of reporters, tags, or human disease variants can be used to monitor endothelial activation in real time or to model patient-specific mutations. Tagged knock-in of STING1 or JAK1 enables interaction studies and localization experiments. Knock-in models also allow the study of regulatory elements that control activation states.
Overexpression
Overexpression of genes such as IL33 or constitutively active STING1 can drive endothelial activation and immune response in vitro and in vivo. Overexpression models are useful for testing sufficiency of a candidate gene to induce GO:0002264. They can also be combined with knockout backgrounds to dissect epistasis.
How EDITGENE Supports endothelial cell activation involved in immune response Research
Researchers studying endothelial cell activation involved in immune response-related genes often need to determine whether a candidate gene is causally involved in the activation process or merely correlated with it. This requires precise genetic models that can knock out, mutate, tag, or overexpress the gene of interest in endothelial cells. EDITGENE provides a comprehensive suite of CRISPR-based services to support such studies, from single-gene editing to library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for endothelial cell activation involved in immune response research.
Frequently Asked Questions About endothelial cell activation involved in immune response
What is GO:0002264 endothelial cell activation involved in immune response?
GO:0002264 is a biological process term describing the change in morphology or behavior of an endothelial cell after exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response.
What genes are involved in endothelial cell activation involved in immune response?
Genes implicated in this process include STING1, JAK1, IL33, complement components, adhesion molecules, and chemokines, based on studies in sepsis, vasculitis, atherosclerosis, and cancer.
How is endothelial cell activation involved in immune response studied?
It is studied using single-cell RNA profiling, STING-JAK1 pathway analysis, neutrophil-endothelial co-culture, complement crosstalk assays, and CRISPR-based gene editing.
Why is endothelial cell activation important in sepsis?
In sepsis, neutrophil extracellular traps and neutrophil-derived factors promote endothelial dysfunction, contributing to vascular leakage and organ failure.
What is the role of STING-JAK1 in endothelial activation?
Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity, indicating a functional signaling module in activated endothelium.
How does IL-33 relate to endothelial activation?
IL-33 is released as a potent extracellular cytokine that can act on endothelial and immune cells, providing a soluble trigger for activation.
What is the link between complement and endothelial activation?
Complement-dendritic cell-endothelial crosstalk in vascular inflammation shows that complement components participate in activating endothelial cells.
Which diseases are associated with endothelial cell activation involved in immune response?
Sepsis, giant cell arteritis, carotid atherosclerosis, cerebrovascular events, and cancer are associated with this process.
Can CRISPR be used to study endothelial cell activation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test causality of candidate genes in endothelial activation.
What cell models are suitable for studying GO:0002264?
Endothelial cell lines, primary endothelial cells, and co-culture systems with neutrophils or dendritic cells are suitable, especially when combined with CRISPR editing.
Conclusion
GO:0002264 endothelial cell activation involved in immune response is a central biological process that links vascular biology to immunology. The QuickGO definition provides a precise framework, and the verified literature demonstrates its relevance to sepsis, giant cell arteritis, atherosclerosis, cerebrovascular events, and cancer. Key genes such as STING1, JAK1, and IL33, along with complement components and adhesion molecules, are promising targets for functional studies. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with single-cell and signaling assays, offer powerful tools to dissect the mechanisms of this process and to identify therapeutic opportunities.
References
- 1. Zhang H et al.. 2023. Neutrophil, neutrophil extracellular traps and endothelial cell dysfunction in sepsis.. Clin Transl Med 13(1):e1170 PMID: 36629024
- 2. Geldhof V et al.. 2022. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.. Nat Commun 13(1):5511 PMID: 36127427
- 3. Cayrol C et al.. 2022. Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine.. Cytokine 156:155891 PMID: 35640416
- 4. Paroli M et al.. 2024. Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.. Cells 13(3) PMID: 38334659
- 5. Yang R et al.. 2024. Lung single-cell RNA profiling reveals response of pulmonary capillary to sepsis-induced acute lung injury.. Front Immunol 15:1308915 PMID: 38348045
- 6. Zhang H et al.. 2025. Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity.. J Clin Invest 135(2) PMID: 39817453
- 7. Tan J et al.. 2023. Single-Cell Transcriptomics Reveals Crucial Cell Subsets and Functional Heterogeneity Associated With Carotid Atherosclerosis and Cerebrovascular Events.. Arterioscler Thromb Vasc Biol 43(12):2312-2332 PMID: 37881939
- 8. Gregori S et al.. 2026. The complement-dendritic cell-endothelial cell crosstalk in vascular inflammation.. Cardiovasc Res 122(7):819-834 PMID: 41410132
